Cytonics Selects CARA Life Sciences Platform for Rapid eTMF System Implementation

LONDON - Rezul -- Cytonics, a biotechnology research and development company specialising in diagnostics and therapeutics for osteoarthritis, has selected Generis, the provider of the AI-enabled CARA Life Sciences Platform, to manage its electronic Trial Master File (eTMF) and enhance operational efficiency and productivity.

Faced with a need for rapid implementation, Cytonics sought a solution that could be deployed quickly without compromising on capabilities or compliance. The CARA Life Sciences Platform provided the ideal fit: a pre-validated, out-of-the-box eTMF solution that met all functional and regulatory requirements.

"We needed a solution that could be up and running quickly, without a lengthy and complex onboarding process," said Joey Bose, President and CEO at Cytonics. "CARA met all of our requirements—user-friendly, compliant, and ready to go in record time."

CARA's eTMF application delivers a fully compliant, audit-ready environment for managing clinical trial documentation, supported by robust metadata management, workflow automation, and seamless integration capabilities. It also includes DIA reference model alignment, automated trial and site setup, and an integrated site portal for streamlined collaboration.

More on Rezul News

• Harvest Properties Acquires Two San Francisco Bay Area Self Storage Facilities for $44.2 Million
• Georgia's Traditions of Braselton to Host Spring Open House Event
• ScreenPoints Puts Film Investors in the Credits—and in the Money With New FinTech Platform
• Pathways to Adulthood Conference May 17 at Melville Marriott Honoring NYS Assembly Member Jodi Giglio, Suffolk County Legislator Nick Caracappa
• Adster Techologies awarded US Patent for breakthrough innovation in reducing latency in Ad Serving

"We're proud to support Cytonics in their mission to improve treatment outcomes for patients around the world," said Max Kelleher, CEO at Generis. "The CARA Life Sciences Platform is a perfect match for companies of all sizes, backed by the depth of experience and innovation our team brings to every project."

By adopting CARA, Cytonics gains a scalable platform that supports future growth and expansion. CARA's built-in AI Assistant further boosts productivity by enabling intuitive access to information and insights—empowering teams to "Chat with Data" for faster, more informed decision-making.

About Generis

Generis is a UK-headquartered developer of world-class data, content and business process management for regulated industries globally. 60% of the top 20 life sciences companies rely on Generis' flagship CARA™ Life Sciences Platform, including AbbVie, UCB, Biogen, Reckitt, Bristol Myers Squibb, Bayer, Pfizer, and Merck KGaA. Today Generis serves more than 750,000 users worldwide, across use cases ranging from RIM, Regulatory / R&D and Safety to Clinical, Non-clinical, Quality GxP, CMC, Pharmacovigilance, Medical Information / Medical Affairs applications and more. More here.

More on Rezul News

• Flexi-View Lending Closes $5.05 Million Residential Acquisition Loan in Billings, Montana
• Robert Fabbio Inducted into the Austin Technology Council Hall of Fame
• Data Driven Design Turns Toronto Houses into Smart Fourplexes
• Cybersecurity is Protecting Your Personal Information and Your Portfolio
• Maui Luxury Real Estate Shares May Properties for Sale!

About Cytonics Corporation
Cytonics is a biotechnology company pioneering treatments in regenerative medicine, with a focus on protein-based therapies for degenerative joint conditions. The company's lead product, CYT-108, is a proprietary fusion protein targeting inflammation in osteoarthritis and other musculoskeletal disorders. More here.